Legend scientific founder returns to ASCO with new ambition for high-yield, non-gene-editing CAR-T platform Read more →

AstraZeneca, after phase 3 miss, posts subgroup data behind pitch for rare disease approval Read more →

Agios’ next-gen PK drug fails blood cancer study but sickle cell disease ambitions remain undimmed Read more →